Xenotransplantation: The 'Bridge' Strategy Gains Traction After Major Trial

The case of 66-year-old Tim Andrews has redefined the potential of xenotransplantation—the practice of transplanting animal organs into humans. While traditionally viewed as a quest for permanent replacements for scarce human organs, Andrews' experience suggests a new, more achievable role: a temporary "bridge" to keep patients off dialysis while awaiting a suitable human donor. A Modified Porcine Kidney's Nine-Month Tenure Andrews received a genetically modified kidney from a Yucatan pig. To prevent his immune system from rejecting the foreign organ, a team at Harvard Medical School, led by Leonardo Riella, performed extensive genomic editing on the pig's kidney. The DNA underwent 69 specific alterations: Masking: Three deletions were made to hide pig antigens from the recipient's immune system. Safety: Fifty-nine inactivations were performed to disable the pig's endogenous retroviruses. Adaptation: Seven insertions were introduced to help stabilize blood clotting and reduce inflammation. The kidney began functioning immediately. However, a systemic conflict emerged between the need to protect the transplant and maintain the patient's overall health. Andrews was prescribed immunosuppressants to prevent rejection. When he contracted a Staphylococcus aureus infection, his doctors reduced the dosage of these drugs to allow his body to fight the bacteria. This compromise weakened the organ's defenses, leading to thrombotic microangiopathy—damage to small blood vessels. After 271 days, the porcine kidney had to be removed.